摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3'-脱氧-2',3'-二去氢-2'氟胸苷 | 122757-54-4

中文名称
3'-脱氧-2',3'-二去氢-2'氟胸苷
中文别名
——
英文名称
1-(3-deoxy-2,3-didehydro-2-fluoro-β-D-glycero-2-enopentofuranosyl)thymine
英文别名
1-(2,3-dideoxy-2-fluoro-β-D-glycero-pent-2-enofuranosyl)thymine;1-(2,3-dideoxy-2-fluoro-β-D-glycero-2-enofuranosyl)thymine;2',3'-dideoxy-2',3'-didehydro-2'-fluorothymidine;3'-deoxy-2',3'-didehydro-2'-fluorothymidine;3'-Deoxy-2',3'-didehydro-2'fluorothymidine;1-[(2R,5S)-3-fluoro-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4-dione
3'-脱氧-2',3'-二去氢-2'氟胸苷化学式
CAS
122757-54-4
化学式
C10H11FN2O4
mdl
——
分子量
242.207
InChiKey
VVHNXFRGXWUNCK-IMTBSYHQSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -1
  • 重原子数:
    17
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.4
  • 拓扑面积:
    78.9
  • 氢给体数:
    2
  • 氢受体数:
    5

SDS

SDS:e09c6f41f233192f266fca918473e7b2
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3'-脱氧-2',3'-二去氢-2'氟胸苷((hydroxyphosphoryl)bis(oxy))bis(methylene) diisopropyl bis(carbonate)吡啶N-甲基咪唑双(2-氧代-3-恶唑烷基)次磷酰氯 作用下, 以 乙腈 为溶剂, 以27.3 %的产率得到1-((2R,5S)-5-(({di(((isopropoxycarbonyl)oxy)methoxy)phosphoryl}oxy)methyl)-3-fluoro-2,5-dihydrofuran-2-yl)-5-methyl-3H-pyrimidine-2,4-dione
    参考文献:
    名称:
    HALO-DEHYDRO-3'-DEOXYURACIL PHOSPHORAMIDATES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS
    摘要:
    Substituted halo-dehydro-3'-deoxyuracil phosphoramidates and related compounds, pharmaceutical compositions, their use for inhibiting LINE1 reverse transcriptase and/or HERV-K reverse transcriptase activity, and their use in the treatment of medical disorders, such as cancer, are disclosed herein.
    公开号:
    WO2024107850A1
  • 作为产物:
    参考文献:
    名称:
    潜在的抗HIV-1核苷的氟化糖类似物。
    摘要:
    为了获得具有优于AZT,FLT或D4T的治疗指数的药物,合成了抗HIV-1核苷的几种类似物。这些包括2',3'-dideoxy-2',3'-difluoro-5-methyluridine(13),其阿拉伯糖类似物19,arab-5--5-甲基胞嘧啶类似物21、3'-脱氧2',3'-二氢-2'-氟胸苷(25),3'-叠氮基2',3'-二脱氧基2'-氟-5-甲基尿苷(29),2'-叠氮基3'-氟-2',3'-双脱氧-5-甲基尿苷(31)和2'3'-二脱氧-2'-氟-5-甲基尿苷(37)。对这些新核苷在体外针对HIV和猫TLV的活性进行了筛选。没有一种化合物显示出明显的活性。有趣的是,活性抗HIV核苷的糖部分有这么小的修饰(即
    DOI:
    10.1021/jm00109a017
点击查看最新优质反应信息

文献信息

  • Antiviral Activity of Various 1-(2′-Deoxy-β-<scp>d</scp>-lyxofuranosyl), 1-(2′-Fluoro-β-<scp>d</scp>-xylofuranosyl), 1-(3′-Fluoro-β-<scp>d</scp>-arabinofuranosyl), and 2′-Fluoro-2′,3′-didehydro-2′,3′-dideoxyribose Pyrimidine Nucleoside Analogues against Duck Hepatitis B Virus (DHBV) and Human Hepatitis B Virus (HBV) Replication
    作者:Naveen C. Srivastav、Neeraj Shakya、Michelle Mak、Babita Agrawal、D. Lorne Tyrrell、Rakesh Kumar
    DOI:10.1021/jm100803c
    日期:2010.10.14
    3′-fluoroarabinofuranosyl, and 2′-fluoro-2′,3′-didehydro-2′,3′-dideoxyribose pyrimidine nucleoside analogues for antiviral activities against hepatitis B virus. Among the compounds examined, 1-(2-deoxy-β-d-lyxofuranosyl)thymine (23), 1-(2-deoxy-β-d-lyxofuranosyl)-5-trifluoromethyluracil (25), 1-(2-deoxy-2-fluoro-β-d-xylofuranosyl)uracil (38), 1-(2-deoxy-2-fluoro-β-d-xylofuranosyl)thymine (39), 2′,3′-dideoxy-2′,3′-d
    尽管存在成功的疫苗和抗病毒疗法,但乙型肝炎病毒(HBV)的感染仍然是急性和慢性肝病以及高死亡率的全球主要原因。我们合成并评估了几种lyxofuranosyl,2'-fluorooxylofuranosyl,3'-fluoroarabinofuranosyl和2'-fluoro-2',3'-didehydro-2',3'-dideoxyribose嘧啶核苷类似物对乙型肝炎病毒的抗病毒活性。在所检查的化合物中,1-(2-脱氧-β - d-呋喃呋喃糖基)胸腺嘧啶(23),1-(2-脱氧-β - d-呋喃呋喃糖基)-5-三氟甲基尿嘧啶(25),1-(2-脱氧-2-氟-β - d-木呋喃糖基)尿嘧啶(38),1-(2-脱氧-2-氟-β- d-二呋喃呋喃糖基)胸腺嘧啶(39),2',3'-二脱氧-2',3'-二脱氢-2'-氟胸苷(48)和2',3'-二脱氧-2',3'-二脱氢-2在原代鸭肝细胞中发现'
  • Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation
    申请人:Gilead Pharmasset LLC
    公开号:US10100076B2
    公开(公告)日:2018-10-16
    The disclosed invention is a composition for and a method of seating a Flaviviridae (including BVDV and HCV), Orthomyxoviridae (including Influenza A and B) or Paramyxoviridae (including RSV) infection, or conditions related to abnormal cellular proliferation, in a host, including animals, and especially humans, using a nucleoside of general formula (I)-(XXIII) or its pharmaceutically acceptable salt or prodrug. This invention also provides an effective process to quantify the viral load, and in particular BVDV, HCV or West Nile Virus load, in a host, using real-time polymerase chain reaction (“RT-PCR”). Additionally, the invention discloses probe molecules that can fluoresce proportionally to the amount of virus present in a sample.
    所述的发明是关于一种用于在宿主中(包括动物,特别是人类)使用一般式(I)-(XXIII)的核苷或其药用可接受的盐或前药,对Flaviviridae(包括BVDV和HCV)、Orthomyxoviridae(包括流感A和B)或Paramyxoviridae(包括RSV)感染,或与异常细胞增殖相关的疾病进行座位的组合物和方法。该发明还提供了一种有效的过程,用于使用实时聚合酶链反应(“RT-PCR”)在宿主中定量病毒载量,特别是BVDV、HCV或西尼罗河病毒载量。此外,该发明还揭示了可以与样本中存在的病毒量成比例发出荧光的探针分子。
  • Synthesis and antiviral activity of monofluoro and difluoro analogs of pyrimidine deoxyribonucleosides against human immunodeficiency virus (HIV-1)
    作者:Joseph A. Martin、David J. Bushnell、Ian B. Duncan、Stephen J. Dunsdon、Michael J. Hall、Peter J. Machin、John H. Merrett、Kevin E. B. Parkes、Noel A. Roberts
    DOI:10.1021/jm00170a015
    日期:1990.8
    A range of 2'-fluoro and 2',3'-difluoro analogues of pyrimidine deoxyribonucleosides have been synthesized and evaluated against human immunodeficiency virus (HIV-1) in a human lymphoblastoid cell line. Among these compounds, 1-(2,3-dideoxy-2-fluoro-beta-D-threopentofuranosyl)cytosine (12), 2',3'-didehydro-2',3'-dideoxy-2'-fluorocytidine (35), 1-(2,3-dideoxy-2,3-difluoro-beta-D-arabinofuranosyl)cytosine
    合成了一系列嘧啶脱氧核糖核苷的2'-氟和2',3'-二氟类似物,并在人淋巴母细胞样细胞系中针对人免疫缺陷病毒(HIV-1)进行了评估。在这些化合物中,1-(2,3-二脱氧-2-氟-β-D-叔戊基呋喃糖基)胞嘧啶(12),2',3'-二脱氢-2',3'-二脱氧-2'-氟胞苷(35) ),1-(2,3-dideoxy-2,3-difluoro-beta-D-arabinofuranosyl)cytosine(41)和3'-deoxy-2',3'-deidehydro-2'-fluorothymidine(45)为被发现具有显着的抗病毒活性,IC50值分别为0.65、10、10和100 microM。讨论了构效关系。
  • Synthesis and anti-HIV activity of several 2'-fluoro-containing pyrimidine nucleosides
    作者:Roman Z. Sterzycki、Ismail Ghazzouli、Vera Brankovan、John C. Martin、Muzammil M. Mansuri
    DOI:10.1021/jm00170a017
    日期:1990.8
    Several 2'-fluoroarabino-2',3'-dideoxy- and 2'-fluoro-2',3'-unsaturated 2',3'-dideoxy pyrimidine nucleoside analogues are reported. The saturated analogues 1-(2,3-dideoxy-2-fluoro-beta-D-threo-pentofuranosyl)thymine (2'-threo-FddT, 33), 1-(2,3-dideoxy-2-fluoro-beta-D-threo-pentofuranosyl)uracil (2'-threo-FddU, 22) were readily prepared from the corresponding 2'-deoxy-2'-fluoroarabinosyl nucleoside analogue
    报道了几种2'-氟阿拉伯糖-2',3'-二脱氧-和2'-氟-2',3'-不饱和的2',3'-二脱氧嘧啶核苷类似物。饱和的类似物1-(2,3-二脱氧-2-氟-β-D-苏-五氟呋喃糖基)胸腺嘧啶(2'-threo-FddT,33),1-(2,3-二脱氧-2-氟-β-胸腺嘧啶通过相应的2'-脱氧-2'-氟阿拉伯糖基核苷类似物,通过3'-OH的自由基脱氧,可以轻松制备-D-苏-五氟呋喃糖基)尿嘧啶(2'-苏-FddU,22)。不饱和化合物1-(2,3-二脱氧-2-氟-β-D-甘油-戊-2-烯呋喃糖基)胸腺嘧啶(2'-Fd4T,40)和1- [5-O-(单甲氧基三苯甲基)通过O-2,3'-脱水-2'-氟代-的消除反应,合成了-2-氟-2,3-二脱氧-β-D-甘油-pen t-2--呋喃糖基]尿嘧啶(39)。 lyxo衍生物在基本条件下。胞苷类似物28和41是通过氨基化相应的尿苷衍生物制备的;使化合物28和41脱保护,得到1-(2
  • Modified nucleosides for the treatment of viral infections and abnormal cellullar proliferation
    申请人:Stuyver Lieven
    公开号:US20110269707A1
    公开(公告)日:2011-11-03
    The disclosed invention is a composition for and a method of treating a Flaviviridae (including BVDV and HCV), Orthomyxoviridae (including Influenza A and B) or Paramyxoviridae (including RSV) infection, or conditions related to abnormal cellular proliferation, in a host, including animals, and especially humans, using a nucleoside of general formula (I)-(XXIII) or its pharmaceutically acceptable salt or prodrug. This invention also provides an effective process to quantify the viral load, and in particular BVDV, HCV or West Nile Virus load, in a host, using real-time polymerase chain reaction (“RT-PCR”). Additionally, the invention discloses probe molecules that can fluoresce proportionally to the amount of virus present in a sample.
    本公开发明涉及一种用于治疗Flaviviridae(包括BVDV和HCV)、Orthomyxoviridae(包括甲型和乙型流感)或Paramyxoviridae(包括RSV)感染或与异常细胞增殖相关的条件的组合物和方法,适用于宿主,包括动物,特别是人类,使用通式(I)-(XXIII)的核苷或其药学上可接受的盐或前药。本发明还提供了一种有效的过程,用于定量病毒载量,特别是BVDV、HCV或西尼罗河病毒载量,在宿主中使用实时聚合酶链反应(“RT-PCR”)。此外,本发明还揭示了探针分子,可以与样品中存在的病毒数量成比例地发出荧光。
查看更多

同类化合物

顺式5-氟-1-[2-(羟甲基)-1,3-氧硫杂环戊-5-基]-2,4(1H,3H)-嘧啶二酮-13C,15N2 顺式5-氟-1-[2-(羟甲基)-1,3-氧硫杂环戊-5-基]-2,4(1H,3H)-嘧啶二酮 顺-5-氟-1-[2-[[[[(((1,1-二甲基乙基)二甲基甲硅烷基]氧基]甲基]-1,3-氧杂硫杂环戊-5-基]-2,4(1H,3H)-嘧啶二酮-13C,15N2 顺-5-氟-1-[2-[[[[(((1,1-二甲基乙基)二甲基甲硅烷基]氧基]甲基]-1,3-氧杂硫杂环戊-5-基]-2,4(1H,3H)-嘧啶二酮 阿巴卡韦羧酸盐 阿巴卡韦相关物质D 阿巴卡韦杂质F 阿巴卡韦杂质 阿巴卡韦中间体A5 阿巴卡韦5’-磷酸酯 阿巴卡韦,拉米夫定混合物 阿巴卡韦 芒霉素 艾夫他滨 腺苷基(3'-5')胞苷基(3'-5')胞苷游离酸 脱氧假尿苷 胸苷酰-(5'-3')-胸苷酰-(5'-3')-胸苷酰-(5'-3')-5'-胸苷酸 胰腺癌RX-3117 硫酸阿巴卡韦 甲基磷羧酸氢[(2S,5R)-5-(4-氨基-2-羰基嘧啶-1(2H)-基)-2,5-二氢呋喃-2-基]甲酯 瓶型酵母D 瓶型酵母A 环戊烯基尿嘧啶 水杨酸拉米呋啶 氟达拉滨EP杂质H 曲沙他滨 拉米夫定相关化合物(Α-TROXACITABINE) 拉米夫定杂质Ⅲ1-[(2R,5S)-2-羟甲基-1,3-氧硫杂环戊-5-基]-嘧啶-2,4(1H,3H)-酮 拉米夫定杂质1 拉米夫定S-氧化物(异构体混合物) 拉米夫定 拉米夫定 拉夫米定EP杂质J 拉夫米定EP杂质H 扎西他宾 恩替卡韦相关物质A 恩替卡韦一水合物 恩曲他滨杂质16 恩曲他滨S-氧化物 恩曲他滨 恩曲他滨 怀俄苷三乙酸酯 怀俄苷 己二酸,聚合1,2-丁二醇 外消旋拉米夫定酸 吡唑霉素 司他夫定 反式-阿巴卡韦盐酸盐 卡波啶 卡巴韦